Search

Your search keyword '"Berneman, Zwi"' showing total 32 results
Start Over Author "Berneman, Zwi" Database OAIster
32 results on '"Berneman, Zwi"'

1. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit.METHODSAdults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS.RESULTSThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P =.0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P =.0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P =.575).CONCLUSIONAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

2. Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssens, Ann, Berneman, Zwi N, Offner, Fritz, Snauwaert, Sylvia, Mineur, Philippe, Vanstraelen, Gaetan, Meers, Stef, Spoormans, Isabelle, Bron, Dominique, Vande Broek, Isabelle, Van Bogaert, Charlotte, De Beleyr, Birgit, Smet, Ann, Nielsen, Lasse, Wapenaar, Robert, André, Marc, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssens, Ann, Berneman, Zwi N, Offner, Fritz, Snauwaert, Sylvia, Mineur, Philippe, Vanstraelen, Gaetan, Meers, Stef, Spoormans, Isabelle, Bron, Dominique, Vande Broek, Isabelle, Van Bogaert, Charlotte, De Beleyr, Birgit, Smet, Ann, Nielsen, Lasse, Wapenaar, Robert, and André, Marc

Abstract

The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM) in Belgium. This interim analysis reports results for patients with CLL, with a median follow-up of 34 months. Overall, patients had predominantly relapsed/refractory disease (73%) and were elderly (median age 72 years) with high-risk features such as del17p and/or TP53 mutations (59%). Patients were included either prospectively or retrospectively, and the total patient population effectiveness results were adjusted with left truncation. In the effectiveness population (N = 221: prospective, n = 71; retrospective, n = 150), the overall response rate was 90.0%. Median progression-free survival was 38.3 months (prospective, not estimable; retrospective, 51.5 months) and median overall survival was not yet estimable in the total, prospective and retrospective groups. Treatment-emergent adverse events (TEAEs) for the prospective and retrospective groups are reported separately. Any-grade TEAEs of interest in the prospective/retrospective groups included infections (67.1%/60.1%), diarrhea (20.5%/10.5%), hypertension (16.4%/9.8%) and atrial fibrillation (12.3%/7.2%). Major bleeding was reported in 5.5%/3.3% of prospective/retrospective patients, with little difference observed between those receiving versus not receiving antithrombotic treatment. Discontinuations due to toxicity were reported in 10.5% of patients. Results from this interim analysis show treatment with ibrutinib to be effective and tolerable, with no new safety signals observed. Future analyses will report on longer-term follow-up.

Published
2022

3. Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study

Author

Janssens, Ann, Berneman, Zwi Nisan, Offner, Fritz, Snauwaert, Sylvia, Mineur, Philippe, Vanstraelen, Gaetan, Meers, Stef, Spoormans, Isabelle, Bron, Dominique, Vande Broek, Isabelle, Van Bogaert, Charlotte, De Beleyr, Birgit, Smet, Ann, Nielsen, Lasse, Wapenaar, Robert, André, Marc, Janssens, Ann, Berneman, Zwi Nisan, Offner, Fritz, Snauwaert, Sylvia, Mineur, Philippe, Vanstraelen, Gaetan, Meers, Stef, Spoormans, Isabelle, Bron, Dominique, Vande Broek, Isabelle, Van Bogaert, Charlotte, De Beleyr, Birgit, Smet, Ann, Nielsen, Lasse, Wapenaar, Robert, and André, Marc

Abstract

The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM) in Belgium. This interim analysis reports results for patients with CLL, with a median follow-up of 34 months. Overall, patients had predominantly relapsed/refractory disease (73%) and were elderly (median age 72 years) with high-risk features such as del17p and/or TP53 mutations (59%). Patients were included either prospectively or retrospectively, and the total patient population effectiveness results were adjusted with left truncation. In the effectiveness population (N = 221: prospective, n = 71; retrospective, n = 150), the overall response rate was 90.0%. Median progression-free survival was 38.3 months (prospective, not estimable; retrospective, 51.5 months) and median overall survival was not yet estimable in the total, prospective and retrospective groups. Treatment-emergent adverse events (TEAEs) for the prospective and retrospective groups are reported separately. Any-grade TEAEs of interest in the prospective/retrospective groups included infections (67.1%/60.1%), diarrhea (20.5%/10.5%), hypertension (16.4%/9.8%) and atrial fibrillation (12.3%/7.2%). Major bleeding was reported in 5.5%/3.3% of prospective/retrospective patients, with little difference observed between those receiving versus not receiving antithrombotic treatment. Discontinuations due to toxicity were reported in 10.5% of patients. Results from this interim analysis show treatment with ibrutinib to be effective and tolerable, with no new safety signals observed. Future analyses will report on longer-term follow-up., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

4. Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS).

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Poiré, Xavier, Graux, Carlos, Ory, Aurélie, Herman, Julie, Baron, Frédéric, Schoemans, Hélène, Lewalle, Philippe, De Becker, Ann, Deeren, Dries, Berneman, Zwi, Kerre, Tessa, Zachée, Pierre, Selleslag, Dominik, Beguin, Yves, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Poiré, Xavier, Graux, Carlos, Ory, Aurélie, Herman, Julie, Baron, Frédéric, Schoemans, Hélène, Lewalle, Philippe, De Becker, Ann, Deeren, Dries, Berneman, Zwi, Kerre, Tessa, Zachée, Pierre, Selleslag, Dominik, and Beguin, Yves

Published
2021

5. Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium

Author

Hematology Department - University Hospitals Leuven, Leuven, Devos, Timothy, Verhoef, Gregor, Steel, Eva, Mazure, Dominiek, Lewalle, Philippe, Bron, Dominique, Berneman, Zwi, Benghiat, Fleur Samantha, Mineur, Philippe, Theunissen, Koen, Zachée, Pierre, Doyen, Chantal, Put, Natalie, Lejeune, Marie, Van Eygen, Koen, Havelange, Violaine, Reusens, Michael, Pluymers, Wim, Peeters, Karen, Hematology Department - University Hospitals Leuven, Leuven, Devos, Timothy, Verhoef, Gregor, Steel, Eva, Mazure, Dominiek, Lewalle, Philippe, Bron, Dominique, Berneman, Zwi, Benghiat, Fleur Samantha, Mineur, Philippe, Theunissen, Koen, Zachée, Pierre, Doyen, Chantal, Put, Natalie, Lejeune, Marie, Van Eygen, Koen, Havelange, Violaine, Reusens, Michael, Pluymers, Wim, and Peeters, Karen

Abstract

To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context) between May 2013 and May 2016. Data collection took place between October 2016 and February 2017. Results: All 60 participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due to side effects occurred later for imatinib- or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with ≥MR 4.5 at interruption/discontinuation and ≥11-month follow-up who had not restarted treatment maintained the response. Conclusion: Although TKIs are used for long-term CML treatment, physicians sometimes recommend interruptions/discontinuations. In this study, interruptions/discontinuations were mainly caused by side effects or intolerance, rather than TFR attempts.

Published
2019

6. Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium

Author

Devos, Timothy, Verhoef, Gregor E G, Steel, Eva, Mazure, Dominiek, Lewalle, Philippe, Bron, Dominique, Berneman, Zwi Nisan, Benghiat, Fleur, Mineur, Philippe, Theunissen, Koen, Zachée, Pierre, Doyen, Chantal, Put, Natalie, Lejeune, Marie, Van Eygen, Koen, Havelange, Violaine, Reusens, Michael, Pluymers, Wim, Peeters, Karen, Devos, Timothy, Verhoef, Gregor E G, Steel, Eva, Mazure, Dominiek, Lewalle, Philippe, Bron, Dominique, Berneman, Zwi Nisan, Benghiat, Fleur, Mineur, Philippe, Theunissen, Koen, Zachée, Pierre, Doyen, Chantal, Put, Natalie, Lejeune, Marie, Van Eygen, Koen, Havelange, Violaine, Reusens, Michael, Pluymers, Wim, and Peeters, Karen

Abstract

Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context) between May 2013 and May 2016. Data collection took place between October 2016 and February 2017. Results: All 60 participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due to side effects occurred later for imatinib- or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with ≥MR 4.5 at interruption/discontinuation and ≥11-month follow-up who had not restarted treatment maintained the response. Conclusion: Although TKIs are used for long-term CML treatment, physicians sometimes recommend interruptions/discontinuations. In this study, interruptions/discontinuations were mainly caused by side effects or intolerance, rather than TFR attempts., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

7. In Vivo Interleukin-13-Primed Macrophages Contribute to Reduced Alloantigen-Specific T Cell Activation and Prolong Immunological Survival of Allogeneic Mesenchymal Stem Cell Implants

Author

Hoornaert, Chloé C.J., Verbeeck, Louca, Quarta, Alessandra, De Vocht, Nathalie, Lemmens, Evi, Goossens, Herman, van der linden, Annemie, Roobrouck, Valerie V.D., Verfaillie, Catherine, Hendrix, Sven, Moser, Muriel, Luyckx, Evi, Berneman, Zwi Nisan, Ponsaerts, Peter, Reekmans, Kristien, Dhainaut, Maxime, Guglielmetti, Caroline, Le Blon, Debbie, Dooley, Dearbhaile, Fransen, Erik, Daans, Jasmijn, Hoornaert, Chloé C.J., Verbeeck, Louca, Quarta, Alessandra, De Vocht, Nathalie, Lemmens, Evi, Goossens, Herman, van der linden, Annemie, Roobrouck, Valerie V.D., Verfaillie, Catherine, Hendrix, Sven, Moser, Muriel, Luyckx, Evi, Berneman, Zwi Nisan, Ponsaerts, Peter, Reekmans, Kristien, Dhainaut, Maxime, Guglielmetti, Caroline, Le Blon, Debbie, Dooley, Dearbhaile, Fransen, Erik, and Daans, Jasmijn

Abstract

Transplantation of mesenchymal stem cells (MSCs) into injured or diseased tissue—for the in situ delivery of a wide variety of MSC-secreted therapeutic proteins—is an emerging approach for the modulation of the clinical course of several diseases and traumata. From an emergency point-of-view, allogeneic MSCs have numerous advantages over patient-specific autologous MSCs since “off-the-shelf” cell preparations could be readily available for instant therapeutic intervention following acute injury. Although we confirmed the in vitro immunomodulatory capacity of allogeneic MSCs on antigen-presenting cells with standard coculture experiments, allogeneic MSC grafts were irrevocably rejected by the host's immune system upon either intramuscular or intracerebral transplantation. In an attempt to modulate MSC allograft rejection in vivo, we transduced MSCs with an interleukin-13 (IL13)-expressing lentiviral vector. Our data clearly indicate that prolonged survival of IL13-expressing allogeneic MSC grafts in muscle tissue coincided with the induction of an alternatively activated macrophage phenotype in vivo and a reduced number of alloantigen-reactive IFNγ- and/or IL2-producing CD8+ T cells compared to nonmodified allografts. Similarly, intracerebral IL13-expressing MSC allografts also exhibited prolonged survival and induction of an alternatively activated macrophage phenotype, although a peripheral T cell component was absent. In summary, this study demonstrates that both innate and adaptive immune responses are effectively modulated in vivo by locally secreted IL13, ultimately resulting in prolonged MSC allograft survival in both muscle and brain tissue. Stem Cells 2016;34:1971–1984., SCOPUS: ar.j, FLWOA, info:eu-repo/semantics/published

Published
2016

8. Distinct in vitro properties of embryonic and extraembryonic fibroblast-like cells are reflected in their in vivo behavior following grafting in the adult mouse brain

Author

Costa, Roberta, Bergwerf, Irene, Santermans, Eva, De Vocht, Nathalie, Praet, Jelle, Daans, Jasmijn, Le Blon, Debbie, Hoornaert, Chloé, Reekmans, Kristien, Hens, Niel, Goossens, Herman, Berneman, Zwi, Parolini, Ornella, Alviano, Francesco, Ponsaerts, Peter, Parolini, Ornella (ORCID:0000-0002-5211-6430), Costa, Roberta, Bergwerf, Irene, Santermans, Eva, De Vocht, Nathalie, Praet, Jelle, Daans, Jasmijn, Le Blon, Debbie, Hoornaert, Chloé, Reekmans, Kristien, Hens, Niel, Goossens, Herman, Berneman, Zwi, Parolini, Ornella, Alviano, Francesco, Ponsaerts, Peter, and Parolini, Ornella (ORCID:0000-0002-5211-6430)

Published
2015

9. Myelofibrosis patients in Belgium: disease characteristics.

Author

Devos, Thibaut, Zachée, Pierre, Bron, Dominique, Noens, Lucien, Droogenbroeck, Jan Van, Mineur, Philippe, Beguin, Yves, Berneman, Zwi, Benghiat, Fleur, Kentos, Alain, Chatelain, Christian, Demuynck, Hilde, Lemmens, Jan, Eygen, Koen Van, Theunissen, Koen, Trullemans, Fabienne, Pierre, Pascal, Pluymers, Wim, Knoops, Laurent, Devos, Thibaut, Zachée, Pierre, Bron, Dominique, Noens, Lucien, Droogenbroeck, Jan Van, Mineur, Philippe, Beguin, Yves, Berneman, Zwi, Benghiat, Fleur, Kentos, Alain, Chatelain, Christian, Demuynck, Hilde, Lemmens, Jan, Eygen, Koen Van, Theunissen, Koen, Trullemans, Fabienne, Pierre, Pascal, Pluymers, Wim, and Knoops, Laurent

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2014

10. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Author

Willemze, Roel, Suciu, Stefan, Meloni, Giovanna, Labar, Boris, Marie, Jean Pierre, Halkes, Constantijn CJ, Muus, Petra, Mistrik, Martin, Amadori, Sergio, Specchia, Giorgina, Fabbiano, Francesco, Nobile, Francesco, Sborgia, Marco, Camera, Andrea, Selleslag, Dominik, Lefrère, Francois, Magro, Domenico, Sica, Simona, Cantore, Nicola, Beksac, Meral Sinan, Berneman, Zwi, Thomas, Xavier, Melillo, Lorella, Guimaraes, Jose E, Leoni, Pietro, Luppi, Mario, Mitra, Maria E, Bron, Dominique, Fillet, Georges, Marijt, Erik EW, Venditti, Adriano, Hagemeijer, Anne, Mancini, M., Jansen, Joop, Cilloni, Daniela, Meert, L, Fazi, Paola, Vignetti, Marco, Trisolini, Silvia SM, Mandelli, Franco, De Witte, Theo, Willemze, Roel, Suciu, Stefan, Meloni, Giovanna, Labar, Boris, Marie, Jean Pierre, Halkes, Constantijn CJ, Muus, Petra, Mistrik, Martin, Amadori, Sergio, Specchia, Giorgina, Fabbiano, Francesco, Nobile, Francesco, Sborgia, Marco, Camera, Andrea, Selleslag, Dominik, Lefrère, Francois, Magro, Domenico, Sica, Simona, Cantore, Nicola, Beksac, Meral Sinan, Berneman, Zwi, Thomas, Xavier, Melillo, Lorella, Guimaraes, Jose E, Leoni, Pietro, Luppi, Mario, Mitra, Maria E, Bron, Dominique, Fillet, Georges, Marijt, Erik EW, Venditti, Adriano, Hagemeijer, Anne, Mancini, M., Jansen, Joop, Cilloni, Daniela, Meert, L, Fazi, Paola, Vignetti, Marco, Trisolini, Silvia SM, Mandelli, Franco, and De Witte, Theo

Abstract

Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine., info:eu-repo/semantics/published

Published
2014

11. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Author

Willemze, Roel, Suciu, Stefan, Meloni, Giovanna, Labar, Boris, Marie, Jean Pierre, Halkes, Constantijn CJ, Muus, Petra, Mistrik, Martin, Amadori, Sergio, Specchia, Giorgina, Fabbiano, Francesco, Nobile, Francesco, Sborgia, Marco, Camera, Andrea, Selleslag, Dominik, Lefrère, Francois, Magro, Domenico, Sica, Simona, Cantore, Nicola, Beksac, Meral Sinan, Berneman, Zwi, Thomas, Xavier, Melillo, Lorella, Guimaraes, Jose E, Leoni, Pietro, Luppi, Mario, Mitra, Maria E, Bron, Dominique, Fillet, Georges, Marijt, Erik EW, Venditti, Adriano, Hagemeijer, Anne, Mancini, M., Jansen, Joop, Cilloni, Daniela, Meert, L, Fazi, Paola, Vignetti, Marco, Trisolini, Silvia SM, Mandelli, Franco, De Witte, Theo, Willemze, Roel, Suciu, Stefan, Meloni, Giovanna, Labar, Boris, Marie, Jean Pierre, Halkes, Constantijn CJ, Muus, Petra, Mistrik, Martin, Amadori, Sergio, Specchia, Giorgina, Fabbiano, Francesco, Nobile, Francesco, Sborgia, Marco, Camera, Andrea, Selleslag, Dominik, Lefrère, Francois, Magro, Domenico, Sica, Simona, Cantore, Nicola, Beksac, Meral Sinan, Berneman, Zwi, Thomas, Xavier, Melillo, Lorella, Guimaraes, Jose E, Leoni, Pietro, Luppi, Mario, Mitra, Maria E, Bron, Dominique, Fillet, Georges, Marijt, Erik EW, Venditti, Adriano, Hagemeijer, Anne, Mancini, M., Jansen, Joop, Cilloni, Daniela, Meert, L, Fazi, Paola, Vignetti, Marco, Trisolini, Silvia SM, Mandelli, Franco, and De Witte, Theo

Abstract

Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2014

12. MRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients

Author

van Gulck, Ellen, Vlieghe, Erika, Vekemans, Marc, van Tendeloo, Viggo V.F., Van de Velde, Ann, Smits, Evelien, Anguille, Sébastien, Cools, Nathalie, Goossens, Herman, Mertens, Liesbet, De Haes, Winni, Wong, Johnsson, Florence, Eric, Vanham, Guido, Berneman, Zwi Nisan, van Gulck, Ellen, Vlieghe, Erika, Vekemans, Marc, van Tendeloo, Viggo V.F., Van de Velde, Ann, Smits, Evelien, Anguille, Sébastien, Cools, Nathalie, Goossens, Herman, Mertens, Liesbet, De Haes, Winni, Wong, Johnsson, Florence, Eric, Vanham, Guido, and Berneman, Zwi Nisan

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2012

13. Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag -specific immune responses

Author

van Gulck, Ellen, Cools, Nathalie, Atkinson, Derek, Bracke, Lotte, Vereecken, Katleen, Vekemans, Marc, van Tendeloo, Viggo V.F., Berneman, Zwi Nisan, Vanham, Guido, van Gulck, Ellen, Cools, Nathalie, Atkinson, Derek, Bracke, Lotte, Vereecken, Katleen, Vekemans, Marc, van Tendeloo, Viggo V.F., Berneman, Zwi Nisan, and Vanham, Guido

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2012

14. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia

Author

Snauwaert, Sylvia, Vanhee, Stijn, Goetgeluk, Glenn, Verstichel, Greet, van Caeneghem, Yasmine, Velghe, Imke, Philippé, Jan, Berneman, Zwi Nisan, Plum, Jean, Taghon, Tom, Leclercq, Georges, Thielemans, Kris M., Kerre, Tessa, Vandekerckhove, Bart, Snauwaert, Sylvia, Vanhee, Stijn, Goetgeluk, Glenn, Verstichel, Greet, van Caeneghem, Yasmine, Velghe, Imke, Philippé, Jan, Berneman, Zwi Nisan, Plum, Jean, Taghon, Tom, Leclercq, Georges, Thielemans, Kris M., Kerre, Tessa, and Vandekerckhove, Bart

Abstract

Background Criteria for good candidate antigens for immunotherapy of acute myeloid leukemia are high expression on leukemic stem cells in the majority of patients with acute myeloid leukemia and low or no expression in vital tissues. It was shown in vaccination trials that Receptor for Hyaluronic Acid Mediated Motility (RHAMM/HMMR) generates cellular immune responses in patients with acute myeloid leukemia and that these responses correlate with clinical benefit. It is not clear however whether this response actually targets the leukemic stem cell, especially since it was reported that RHAMM is expressed maximally during the G2/M phase of the cell cycle. In addition, tumor specificity of RHAMM expression remains relatively unexplored. Design and Methods Blood, leukapheresis and bone marrow samples were collected from both acute myeloid leukemia patients and healthy controls. RHAMM expression was assessed at protein and mRNA levels on various sorted populations, either fresh or after manipulation. Results High levels of RHAMM were expressed by CD34+CD38+ and CD34- acute myeloid leukemia blasts. However, only baseline expression of RHAMM was measured in CD34+CD38- leukemic stem cells, and was not different from that in CD34+CD38- hematopoietic stem cells from healthy controls. RHAMM was significantly up-regulated in CD34+ cells from healthy donors during in vitro expansion and during in vivo engraftment. Finally, we demonstrated an explicit increase in the expression level of RHAMM after in vitro activation of T cells. Conclusions RHAMM does not fulfill the criteria of an ideal target antigen for immunotherapy of acute myeloid leukemia. RHAMM expression in leukemic stem cells does not differ significantly from the expression in hematopoietic stem cells from healthy controls. RHAMM expression in proliferating CD34+ cells of healthy donors and activated T cells further compromises RHAMM-specific T-cell-mediated immunotherapy. © 2012 Ferrata Storti Foundation., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2012

15. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia

Author

Snauwaert, Sylvia, Vanhee, Stijn, Goetgeluk, Glenn, Verstichel, Greet, van Caeneghem, Yasmine, Velghe, Imke, Philippé, Jan, Berneman, Zwi Nisan, Plum, Jean, Taghon, Tom, Leclercq, Georges, Thielemans, Kris M., Kerre, Tessa, Vandekerckhove, Bart, Snauwaert, Sylvia, Vanhee, Stijn, Goetgeluk, Glenn, Verstichel, Greet, van Caeneghem, Yasmine, Velghe, Imke, Philippé, Jan, Berneman, Zwi Nisan, Plum, Jean, Taghon, Tom, Leclercq, Georges, Thielemans, Kris M., Kerre, Tessa, and Vandekerckhove, Bart

Abstract

Background Criteria for good candidate antigens for immunotherapy of acute myeloid leukemia are high expression on leukemic stem cells in the majority of patients with acute myeloid leukemia and low or no expression in vital tissues. It was shown in vaccination trials that Receptor for Hyaluronic Acid Mediated Motility (RHAMM/HMMR) generates cellular immune responses in patients with acute myeloid leukemia and that these responses correlate with clinical benefit. It is not clear however whether this response actually targets the leukemic stem cell, especially since it was reported that RHAMM is expressed maximally during the G2/M phase of the cell cycle. In addition, tumor specificity of RHAMM expression remains relatively unexplored. Design and Methods Blood, leukapheresis and bone marrow samples were collected from both acute myeloid leukemia patients and healthy controls. RHAMM expression was assessed at protein and mRNA levels on various sorted populations, either fresh or after manipulation. Results High levels of RHAMM were expressed by CD34+CD38+ and CD34- acute myeloid leukemia blasts. However, only baseline expression of RHAMM was measured in CD34+CD38- leukemic stem cells, and was not different from that in CD34+CD38- hematopoietic stem cells from healthy controls. RHAMM was significantly up-regulated in CD34+ cells from healthy donors during in vitro expansion and during in vivo engraftment. Finally, we demonstrated an explicit increase in the expression level of RHAMM after in vitro activation of T cells. Conclusions RHAMM does not fulfill the criteria of an ideal target antigen for immunotherapy of acute myeloid leukemia. RHAMM expression in leukemic stem cells does not differ significantly from the expression in hematopoietic stem cells from healthy controls. RHAMM expression in proliferating CD34+ cells of healthy donors and activated T cells further compromises RHAMM-specific T-cell-mediated immunotherapy. © 2012 Ferrata Storti Foundation., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2012

16. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Author

Labar, Boris, Suciu, Stefan, Willemze, Roel, Muus, Petra, Marie, Jean Pierre, Fillet, Georges, Berneman, Zwi, Jaksic, Branimir, Feremans, Walter, Bron, Dominique, Sinnige, Harm, Mistrik, Martin, Vreugdenhil, Gerard, De Bock, Robrecht, Nemet, Damir, Gilotay, C., Amadori, Sergio, De Witte, Theo, EORTC Leukemia Group, Labar, Boris, Suciu, Stefan, Willemze, Roel, Muus, Petra, Marie, Jean Pierre, Fillet, Georges, Berneman, Zwi, Jaksic, Branimir, Feremans, Walter, Bron, Dominique, Sinnige, Harm, Mistrik, Martin, Vreugdenhil, Gerard, De Bock, Robrecht, Nemet, Damir, Gilotay, C., Amadori, Sergio, De Witte, Theo, and EORTC Leukemia Group

Abstract

Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. Our aim was to determine whether dexamethasone results in a better outcome than prednisolone., Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H. Extramural, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2010

17. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Author

Labar, Boris, Suciu, Stefan, Willemze, Roel, Muus, Petra, Marie, Jean Pierre, Fillet, Georges, Berneman, Zwi, Jaksic, Branimir, Feremans, Walter, Bron, Dominique, Sinnige, Harm, Mistrik, Martin, Vreugdenhil, Gerard, De Bock, Robrecht, Nemet, Damir, Gilotay, C., Amadori, Sergio, De Witte, Theo, EORTC Leukemia Group, Labar, Boris, Suciu, Stefan, Willemze, Roel, Muus, Petra, Marie, Jean Pierre, Fillet, Georges, Berneman, Zwi, Jaksic, Branimir, Feremans, Walter, Bron, Dominique, Sinnige, Harm, Mistrik, Martin, Vreugdenhil, Gerard, De Bock, Robrecht, Nemet, Damir, Gilotay, C., Amadori, Sergio, De Witte, Theo, and EORTC Leukemia Group

Abstract

Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. Our aim was to determine whether dexamethasone results in a better outcome than prednisolone., Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H. Extramural, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2010

18. Laboratory diagnosis and molecular classification of von Willebrand disease.

Author

Gadisseur, Alain, Hermans, Cedric, Berneman, Zwi, Schroyens, Wilfried, Deckmyn, Hans, Michiels, Jan Jacques, Gadisseur, Alain, Hermans, Cedric, Berneman, Zwi, Schroyens, Wilfried, Deckmyn, Hans, and Michiels, Jan Jacques

Abstract

A complete set of laboratory investigations, including bleeding time, PFA-100 closure times, factor VIII (FVIII) coagulant activity (FVIII:C), von Willebrand factor (VWF) ristocetin cofactor (VWF:RCo), collagen binding (VWF:CB), antigen (VWF:Ag) and propeptide (VWFpp), ristocetin-induced platelet aggregation (RIPA), multimeric analysis of VWF and the response of FVIII:C and VWF parameters to desmopressin (DDAVP), is necessary to fully diagnose all variants of von Willebrand disease (VWD) and to discriminate between type 1 and type 2 and between severe VWD type 1 and type 3. The response to DDAVP of VWF parameters is normal in pseudo VWD (mild VWF deficiency due to blood group O), in mild VWD type 1 and in carriers of recessive severe VWD type 1 and 3. The response to DDAVP is rather good but restricted followed by increased clearance in dominant type 1/2E, good but transient in mild type 2A group II, good for VWF:CB, with only poor response for VWF:RCo in 2M and 2U, poor in 2A group I, 2B, 2C and 2D, and very poor or non-responsive in severe recessive VWD type 1 and 3. Homozygosity or double heterozygosity for nonsense (null) mutations in the VWF gene result in recessive VWD type 3. The combination of a nonsense and missense mutation or of two missense mutations (homozygous or double heterozygous) may cause recessive severe VWD type 1. Recessive VWD type 2A subtype IIC (2C) is caused by homozygous or double heterozygous gene defects in the D1-D2 domain. Homozygosity or double heterozygosity for a FVIII binding defect of the VWF is the cause of recessive VWD type 2N (Normandy) characterized by low FVIII:C, mild or moderate VWF deficiency and normal VWF multimers. Dominant VWD type 1/2E is a mixed quantitative and qualitative multimerization defect caused by a heterozygous cysteine mutation in the D3 domain resulting in abnormal multimerization with a secretion and clearance defect of VWF not due to increased proteolysis. Dominant VWD type 1 Vicenza is a qualitative d

Published
2009

19. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

Author

Noens, Lucien, van Lierde, Marie-Anne, De Bock, R, Verhoef, G, Zachée, Pierre, Berneman, Zwi Nisan, Martiat, Philippe, Mineur, Philippe, Van Eygen, Koen, MacDonald, Karen, De Geest, Sabina, Albrecht, Tara, Abraham, Ivo, Noens, Lucien, van Lierde, Marie-Anne, De Bock, R, Verhoef, G, Zachée, Pierre, Berneman, Zwi Nisan, Martiat, Philippe, Mineur, Philippe, Van Eygen, Koen, MacDonald, Karen, De Geest, Sabina, Albrecht, Tara, and Abraham, Ivo

Abstract

Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable., Evaluation Studies, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2009

20. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

Author

Noens, Lucien, van Lierde, Marie-Anne, De Bock, R, Verhoef, G, Zachée, Pierre, Berneman, Zwi Nisan, Martiat, Philippe, Mineur, Philippe, Van Eygen, Koen, MacDonald, Karen, De Geest, Sabina, Albrecht, Tara, Abraham, Ivo, Noens, Lucien, van Lierde, Marie-Anne, De Bock, R, Verhoef, G, Zachée, Pierre, Berneman, Zwi Nisan, Martiat, Philippe, Mineur, Philippe, Van Eygen, Koen, MacDonald, Karen, De Geest, Sabina, Albrecht, Tara, and Abraham, Ivo

Abstract

Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable., Evaluation Studies, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2009

21. Guidelines for the transfusion of red cells

Author

Baele, Philippe, Muylle, Ludo, Noens, Lucien, Gulliksson, Hans, Brand, Anneke, Isbister, James, Van Der Linden, Philippe, Hübner, Rayk, Berneman, Zwi Nisan, Lamy, Maurice, Ferrant, Augustin, Lambermont, Micheline, Sondag, Danielle, Baele, Philippe, Muylle, Ludo, Noens, Lucien, Gulliksson, Hans, Brand, Anneke, Isbister, James, Van Der Linden, Philippe, Hübner, Rayk, Berneman, Zwi Nisan, Lamy, Maurice, Ferrant, Augustin, Lambermont, Micheline, and Sondag, Danielle

Abstract

The following recommendations, which aim at standardising and rationalising clinical indications for the transfusion of red cells in Belgium, were drawn up by a working group of the Superior Health Council. To this end, the Superior Health Council organised an expert meeting devoted to "Guidelines for the transfusion of red cells" in collaboration with the Belgian Hematological Society. The experts discussed the indications for red cell transfusions, the ideal red cell concentrate, the practical issues of administering red cells, and red cell transfusions in patients in a critical condition. The recommendations formulated by the experts were validated by the working group with the purpose of harmonising red cell transfusion in Belgian hospitals., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2008

22. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

Author

Bosly, André, Bron, Dominique, van Hoof, Achiel, De Bock, R, Berneman, Zwi Nisan, Ferrant, Augustin, Kaufman, L., Dauwe, M, Verhoef, G, Bosly, André, Bron, Dominique, van Hoof, Achiel, De Bock, R, Berneman, Zwi Nisan, Ferrant, Augustin, Kaufman, L., Dauwe, M, and Verhoef, G

Abstract

The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like, ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV (cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000. In our sample, the proportion who received each of the three regimens was 78.4, 16.4, and 5.2%, respectively. Of those prescribed CHOP-like regimens, 15% received <80% average relative dose intensity (ARDI). In 210 patients treated with CHOP-21 (77% of the CHOP-like group), median survival was 7.08 years in those who received >90% of the ARDI, significantly longer than in those who received < or = 90% of the ARDI (p = 0.002). Dose reductions and/or delays, mainly due to hematological toxicities, resulted in a reduction in treatment intensity. These data indicate that patient outcome is improved when the intensity of chemotherapy treatment is optimal., Journal Article, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2008

23. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

Author

Bosly, André, Bron, Dominique, van Hoof, Achiel, De Bock, R, Berneman, Zwi Nisan, Ferrant, Augustin, Kaufman, L., Dauwe, M, Verhoef, G, Bosly, André, Bron, Dominique, van Hoof, Achiel, De Bock, R, Berneman, Zwi Nisan, Ferrant, Augustin, Kaufman, L., Dauwe, M, and Verhoef, G

Abstract

The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like, ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV (cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000. In our sample, the proportion who received each of the three regimens was 78.4, 16.4, and 5.2%, respectively. Of those prescribed CHOP-like regimens, 15% received <80% average relative dose intensity (ARDI). In 210 patients treated with CHOP-21 (77% of the CHOP-like group), median survival was 7.08 years in those who received >90% of the ARDI, significantly longer than in those who received < or = 90% of the ARDI (p = 0.002). Dose reductions and/or delays, mainly due to hematological toxicities, resulted in a reduction in treatment intensity. These data indicate that patient outcome is improved when the intensity of chemotherapy treatment is optimal., Journal Article, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2008

24. Guidelines for the transfusion of red cells

Author

Baele, Philippe, Muylle, Ludo, Noens, Lucien, Gulliksson, Hans, Brand, Anneke, Isbister, James, Van Der Linden, Philippe, Hübner, Rayk, Berneman, Zwi Nisan, Lamy, Maurice, Ferrant, Augustin, Lambermont, Micheline, Sondag, Danielle, Baele, Philippe, Muylle, Ludo, Noens, Lucien, Gulliksson, Hans, Brand, Anneke, Isbister, James, Van Der Linden, Philippe, Hübner, Rayk, Berneman, Zwi Nisan, Lamy, Maurice, Ferrant, Augustin, Lambermont, Micheline, and Sondag, Danielle

Abstract

The following recommendations, which aim at standardising and rationalising clinical indications for the transfusion of red cells in Belgium, were drawn up by a working group of the Superior Health Council. To this end, the Superior Health Council organised an expert meeting devoted to "Guidelines for the transfusion of red cells" in collaboration with the Belgian Hematological Society. The experts discussed the indications for red cell transfusions, the ideal red cell concentrate, the practical issues of administering red cells, and red cell transfusions in patients in a critical condition. The recommendations formulated by the experts were validated by the working group with the purpose of harmonising red cell transfusion in Belgian hospitals., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2008

25. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

Author

Zwierzina, Heinz, Suciu, Stefan, Loeffler, Jay S., Neuwirtova, Radana, Fenaux, Pierre, Beksac, Meral Sinan, Harousseau, Jean-Luc, Nuessler, Volkmar, Cermak, Jaroslav, Solbu, Gabriel, Willemze, Roel, De Witte, Theo, Amadori, Sergio, Stryckmans, Pierre, Bron, Dominique, Louwagie, A., Selleslag, Dominik, Peetermans, M., Berneman, Zwi Nisan, Coiffier, Bertrand, Thyss, Antoine, Bourhis, Jean, Fiere, Denis, Zittoun, R, Marie, Jean Pierre, Maraninchi, D., Baumelou, E., Lowenberg, B., Sonnenveld, P., Gerhartz, Heinrich, Ribeiro, Maíra Marques, Ben-Bassat, Isaac, Labar, Boris, Dardenne, Murielle, Zwierzina, Heinz, Suciu, Stefan, Loeffler, Jay S., Neuwirtova, Radana, Fenaux, Pierre, Beksac, Meral Sinan, Harousseau, Jean-Luc, Nuessler, Volkmar, Cermak, Jaroslav, Solbu, Gabriel, Willemze, Roel, De Witte, Theo, Amadori, Sergio, Stryckmans, Pierre, Bron, Dominique, Louwagie, A., Selleslag, Dominik, Peetermans, M., Berneman, Zwi Nisan, Coiffier, Bertrand, Thyss, Antoine, Bourhis, Jean, Fiere, Denis, Zittoun, R, Marie, Jean Pierre, Maraninchi, D., Baumelou, E., Lowenberg, B., Sonnenveld, P., Gerhartz, Heinrich, Ribeiro, Maíra Marques, Ben-Bassat, Isaac, Labar, Boris, and Dardenne, Murielle

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2005

26. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

Author

Zwierzina, Heinz, Suciu, Stefan, Loeffler, Jay S., Neuwirtova, Radana, Fenaux, Pierre, Beksac, Meral Sinan, Harousseau, Jean-Luc, Nuessler, Volkmar, Cermak, Jaroslav, Solbu, Gabriel, Willemze, Roel, De Witte, Theo, Amadori, Sergio, Stryckmans, Pierre, Bron, Dominique, Louwagie, A., Selleslag, Dominik, Peetermans, M., Berneman, Zwi Nisan, Coiffier, Bertrand, Thyss, Antoine, Bourhis, Jean, Fiere, Denis, Zittoun, R, Marie, Jean Pierre, Maraninchi, D., Baumelou, E., Lowenberg, B., Sonnenveld, P., Gerhartz, Heinrich, Ribeiro, Maíra Marques, Ben-Bassat, Isaac, Labar, Boris, Dardenne, Murielle, Zwierzina, Heinz, Suciu, Stefan, Loeffler, Jay S., Neuwirtova, Radana, Fenaux, Pierre, Beksac, Meral Sinan, Harousseau, Jean-Luc, Nuessler, Volkmar, Cermak, Jaroslav, Solbu, Gabriel, Willemze, Roel, De Witte, Theo, Amadori, Sergio, Stryckmans, Pierre, Bron, Dominique, Louwagie, A., Selleslag, Dominik, Peetermans, M., Berneman, Zwi Nisan, Coiffier, Bertrand, Thyss, Antoine, Bourhis, Jean, Fiere, Denis, Zittoun, R, Marie, Jean Pierre, Maraninchi, D., Baumelou, E., Lowenberg, B., Sonnenveld, P., Gerhartz, Heinrich, Ribeiro, Maíra Marques, Ben-Bassat, Isaac, Labar, Boris, and Dardenne, Murielle

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2005

27. Stem cell transplantation in ALL: a donor versus no donor comparison in the EORTC ALL-4 study

Author

Bron, Dominique, Labar, Boris, Suciu, Stefan, Muus, P., Willemze, Roel, Marie, Jean Pierre, Fillet, Georges, Berneman, Zwi Nisan, Jaksic, B., Feremans, Walter, Sinnige, H., Mistrik, M., Vreudgenhil, G., De Bock, R, Nemet, D., Gilotay, C., Amadori, Sergio, De Witte, Theo, Bron, Dominique, Labar, Boris, Suciu, Stefan, Muus, P., Willemze, Roel, Marie, Jean Pierre, Fillet, Georges, Berneman, Zwi Nisan, Jaksic, B., Feremans, Walter, Sinnige, H., Mistrik, M., Vreudgenhil, G., De Bock, R, Nemet, D., Gilotay, C., Amadori, Sergio, and De Witte, Theo

Abstract

for the EORTC leukemia group, info:eu-repo/semantics/published

Published
2002

28. The Belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor

Author

Dresse, Marie-Françoise, Boogaerts, M, Vermylen, C, Noens, Lucien, Ferrant, Augustin, Schots, Rik, Doyen, C, Bron, Dominique, Berneman, Zwi Nisan, Ferster, Alina, Benoît, Yves, Demuynck, H, Beguin, Yves, Dresse, Marie-Françoise, Boogaerts, M, Vermylen, C, Noens, Lucien, Ferrant, Augustin, Schots, Rik, Doyen, C, Bron, Dominique, Berneman, Zwi Nisan, Ferster, Alina, Benoît, Yves, Demuynck, H, and Beguin, Yves

Abstract

info:eu-repo/semantics/published

Published
1999

29. The Belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor

Author

Dresse, Marie-Françoise, Boogaerts, M, Vermylen, C, Noens, Lucien, Ferrant, Augustin, Schots, Rik, Doyen, C, Bron, Dominique, Berneman, Zwi Nisan, Ferster, Alina, Benoît, Yves, Demuynck, H, Beguin, Yves, Dresse, Marie-Françoise, Boogaerts, M, Vermylen, C, Noens, Lucien, Ferrant, Augustin, Schots, Rik, Doyen, C, Bron, Dominique, Berneman, Zwi Nisan, Ferster, Alina, Benoît, Yves, Demuynck, H, and Beguin, Yves

Abstract

info:eu-repo/semantics/published

Published
1999

30. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer

Author

Cometta, Alain, Calandra, Thierry, Gaya, Harold, Zinner, Stephen H., De Bock, Robrecht, Del Favero, Albano, Bucaneve, Giampaolo, Crokaert, Françoise, Kern, Winfried V., Klastersky, Jean, Langenaeken, John, Micozzi, Alessandra, Padmos, Andrew, Paesmans, Marianne, Viscoli, Claudio, Glauser, Michel, Martino, Pietro, Caballero, D., Engelhard, Dan, Shapiro, Merrwyn, Castagnola, E., Massimo, L., Giacchino, R., Sanz, Miguel A, Giacchino, Mareva, Aoun, Michel, Oppenheim, B., D'Antonio, D., Follath, Ferenc, Barbabietola, Giuliana, Menichetti, F., Montillo, M, Van Lint, Maria Teresa, Gibson, B., Resegotti, Luigi, Kibbler, C., Prentice, H., van Hoof, Achiel, Van Landuyt, Herman, Ricci, Paolo, Rosti, Giovanni, Efremidis, Anna, Di Raimondo, F., Hemmer, Robert, Hatjiyanni, M., Seitanides, B., Amsallen, D., Estavoyer, JM, Petrikkos, George, Porcellini, Adolfo, Berneman, Zwi Nisan, Cometta, Alain, Calandra, Thierry, Gaya, Harold, Zinner, Stephen H., De Bock, Robrecht, Del Favero, Albano, Bucaneve, Giampaolo, Crokaert, Françoise, Kern, Winfried V., Klastersky, Jean, Langenaeken, John, Micozzi, Alessandra, Padmos, Andrew, Paesmans, Marianne, Viscoli, Claudio, Glauser, Michel, Martino, Pietro, Caballero, D., Engelhard, Dan, Shapiro, Merrwyn, Castagnola, E., Massimo, L., Giacchino, R., Sanz, Miguel A, Giacchino, Mareva, Aoun, Michel, Oppenheim, B., D'Antonio, D., Follath, Ferenc, Barbabietola, Giuliana, Menichetti, F., Montillo, M, Van Lint, Maria Teresa, Gibson, B., Resegotti, Luigi, Kibbler, C., Prentice, H., van Hoof, Achiel, Van Landuyt, Herman, Ricci, Paolo, Rosti, Giovanni, Efremidis, Anna, Di Raimondo, F., Hemmer, Robert, Hatjiyanni, M., Seitanides, B., Amsallen, D., Estavoyer, JM, Petrikkos, George, Porcellini, Adolfo, and Berneman, Zwi Nisan

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1996

31. Treatment of hairy-cell leukemia with recombinant alpha2-interferon

Author

Berneman, Zwi Nisan, Peetermans, Marc E., Gastl, Günther, Aulitzky, Walter Erich W., Huber, Christoph, Gangji, Diamon, Flament, Jocelyne, Van Camp, Ben, Jochmans, Kristin, Berneman, Zwi Nisan, Peetermans, Marc E., Gastl, Günther, Aulitzky, Walter Erich W., Huber, Christoph, Gangji, Diamon, Flament, Jocelyne, Van Camp, Ben, and Jochmans, Kristin

Abstract

Eleven patients with hairy-cell leukemia (eight with progressive and three with non-progressive disease) were treated with low dose recombinant human alpha2-interferon. After a 3-month treatment period, nine patients showed an improvement and one patient a partial remission. By then, transfusions were not required any more and serious infections were no longer encountered. Four patients were further treated: three for a total period of 9 months and one for 6 months; all of them reached a partial or complete remission. The treatment was equally effective in patients with both progressive and non-progressive disease. Previous absence of response to splenectomy did not preclude a positive effect of IFN therapy. In two patients, IFN dose reduction was necessary due to unremitting flu-like symptoms. © 1986., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1986

32. Treatment of hairy-cell leukemia with recombinant alpha2-interferon

Author

Berneman, Zwi Nisan, Peetermans, Marc E., Gastl, Günther, Aulitzky, Walter Erich W., Huber, Christoph, Gangji, Diamon, Flament, Jocelyne, Van Camp, Ben, Jochmans, Kristin, Berneman, Zwi Nisan, Peetermans, Marc E., Gastl, Günther, Aulitzky, Walter Erich W., Huber, Christoph, Gangji, Diamon, Flament, Jocelyne, Van Camp, Ben, and Jochmans, Kristin

Abstract

Eleven patients with hairy-cell leukemia (eight with progressive and three with non-progressive disease) were treated with low dose recombinant human alpha2-interferon. After a 3-month treatment period, nine patients showed an improvement and one patient a partial remission. By then, transfusions were not required any more and serious infections were no longer encountered. Four patients were further treated: three for a total period of 9 months and one for 6 months; all of them reached a partial or complete remission. The treatment was equally effective in patients with both progressive and non-progressive disease. Previous absence of response to splenectomy did not preclude a positive effect of IFN therapy. In two patients, IFN dose reduction was necessary due to unremitting flu-like symptoms. © 1986., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1986

Catalog

Books, media, physical & digital resources
See catalog results